The East-West Bio Brief

US Commission warns of early-stage China biotech deals; RA Capital opens Shanghai office

10 min Listen to the original Episode page
BiotechChinaUS-China RelationsPharmaVenture CapitalAI in HealthcareRegulatory PolicyM&A

Summary

A US Congressional Commission analyzed 57 licensing deals between US drugmakers and Chinese biotechs from Jan 2023 to Oct 2026, finding that transactions are occurring earlier in development with higher upfront payments, raising concerns about technology transfer. The hosts contrast this regulatory caution with commercial engagement, noting RA Capital's decision to open a Shanghai office despite its criticism of US scrutiny. Specific deal comparisons highlight AbbVie's $40M upfront for Disco's research-stage therapy versus a $650M upfront for RemeGen's clinical-stage drug. Additional industry moves include Merck's partnership with Isomorphic Labs, Sanofi's consideration of an Insmed acquisition, and funding rounds for AI labs and a Hangzhou brain stimulator startup.

Key takeaways

  1. 1
    Merck partners with Isomorphic Labs.

    Unidentified speaker (speaker_0) · 6:56

  2. 2
    Bloomberg reports that Sanofi is weighing a takeover of InSMED

    Ning · 7:24

Episode sections

  1. 0:04 – 1:06

    Intro and AI-voice disclosure

    Hosts introduce the show, disclose AI voice cloning, and state that views are not investment advice.

  2. 1:06 – 3:58

    The commission's warning: 57 deals, earlier and bigger

    A US Congressional Commission analyzed 57 licensing deals between US drugmakers and Chinese biotechs (Jan 2023–Oct 2026), finding deals happen earlier, with higher upfronts, and risk transferring know-how to China.

  3. 3:58 – 4:29

    The counterpoint: RA Capital's door in Shanghai

    RA Capital, a Boston investor critical of US scrutiny, opened an office in Shanghai in mid-October, illustrating the tension between regulatory 'fences' and commercial engagement.

  4. 4:29 – 6:56

    Deal comparisons and Novartis investor day

    The hosts compare AbbVie's $40M upfront for Disco's research-stage therapy vs. its $650M upfront for RemeGen's clinical-stage drug, and discuss Novartis's investor day, including the QCZ484 drug from Argo Biopharma.

  5. 6:56 – 9:03

    Merck, Sanofi, Mega Robo, and Brain Stimulation

    Merck partners with Isomorphic Labs; Sanofi considers buying Insmed; Mega Robo raises funds for AI labs; a Hangzhou startup raises capital for a brain stimulator for depression.

  6. 9:03 – 9:58

    Conclusion and sources

    Hosts summarize the 'fence vs. door' dynamic, note the December 7 comment deadline for Treasury rules, and direct listeners to LinkedIn for transcripts.

Assets discussed

AssetKindStanceContext
SanofiSNYequityneutralSanofi. Bloomberg reports that Sanofi is weighing a takeover of InSMED, the US maker of Brin Supre, a pill for a chronic lung disease called bronchyactasis.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

A US Congressional Commission analyzed 57 licensing deals between 15 of the biggest US drugmakers and 42 Chinese biotech companies from January 2023 to October 2026.

Ning ·1:22

How to verify: Search for the press release 'China is Closing the Biopharma Innovation Gap' from the National Security Commission on Emerging Biotechnology (NSCEB) and verify the deal count and date range in the report or summary. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

The Commission argues that repeat partnerships teach partners how to develop, register, and sell medicines in the US, comparing this to US joint ventures in cars, chips, and industrial chemicals.

Unidentified speaker (UNKNOWN) ·1:53

How to verify: Read the NSCEB report 'China is Closing the Biopharma Innovation Gap' and locate the section on 'know-how' transfer and the comparison to other industries. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Caitlin Fraser, the Commission's executive director, stated that US-China pharma deals are starting to favor Chinese startups and risk eroding US biotech R&D.

Unidentified speaker (speaker_0) ·2:10

How to verify: Search for Caitlin Fraser's quotes in the NSCEB press release or related news coverage (e.g., Axios, Reuters) from November 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

China published a five-year plan for its pharmaceutical industry in September with goals for more first-in-class drugs and global sales by 2030.

Ning ·2:22

How to verify: Search for China's 'Five-Year Plan for Pharmaceutical Industry' published in September 2026 and verify the 2030 goals. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

The US Treasury proposed a rule under the COINS Act in October to bring biotech into outbound investment programs, with public comments closing December 7.

Ning ·2:44

How to verify: Search the US Treasury Department's Federal Register notices for the COINS Act rule proposal and verify the comment deadline date. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

RA Capital opened an office in Shanghai in mid-October, with 12 people in China, four of them investment professionals.

Unidentified speaker (UNKNOWN) ·3:58

How to verify: Search for 'RA Capital Shanghai office opening' in the South China Morning Post or RA Capital's official announcements for October 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

AbbVie (referred to as APV/Epvi) signed with Disco Pharmaceuticals for $40 million upfront and up to $2.5 billion in option and milestone payments.

Unidentified speaker (UNKNOWN) ·4:35

How to verify: Search for the AbbVie-Disco Pharmaceuticals press release or SEC filing (Form 8-K) and verify the upfront and milestone amounts. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Primary source

Novartis expects sales to grow 5% a year at constant currencies from 2026 to 2031 and raised peak sales forecasts for Casimta to $8 billion, and Scamblix and Legville to $5 billion each.

Ning ·5:55

How to verify: Review Novartis's Investor Day presentation materials from November 2026 and verify the CAGR and peak sales figures. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Novartis's QCZ484 is a twice-yearly RNA silencer for high blood pressure licensed from Argo Biopharma, with Phase 2 trials in Singapore.

Unidentified speaker (UNKNOWN) ·6:30

How to verify: Check Novartis's pipeline database or press release regarding QCZ484 and verify the licensing partner (Argo Biopharma) and trial sites. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Review the full US Congressional Commission report on US-China biotech licensing deals for detailed transaction data and risk assessments.
  • Verify AbbVie's licensing agreements with Disco and RemeGen via SEC filings (e.g., 8-K or 10-K) to confirm upfront payment amounts and deal stages.
  • Check RA Capital's official announcements or press releases regarding the opening of its Shanghai office and its stated rationale.
  • Examine Novartis's investor day presentation materials for details on the QCZ484 drug and Argo Biopharma partnership.
  • Monitor Merck's SEC filings for the Isomorphic Labs partnership terms and scope.
  • Track Sanofi's regulatory filings and press releases for any formal announcement regarding the potential acquisition of Insmed.
  • Verify Mega Robo's funding round details through Crunchbase or PitchBook.
  • Research the Hangzhou brain stimulator startup's technology and clinical stage via medical journals or company press releases.
Full transcriptexpand

0:04Unidentified speaker (UNKNOWN): Is

0:05Unidentified speaker (speaker_0): a license just a license? Washington isn't so sure. A US Congressional Commission went through 57 deals. 57. Its conclusion: big drug makers are buying from Chinese biotechs earlier, paying more upfront, Up front and, in its view, sending know-how back along with the cash. Good fences make good neighbors? That's today's debate. Washington wants a fence. A Boston investor just opened a door in Shanghai, and Novartis put a blood pressure drop from Shanghai on its investor day stage. From Singapore, we can see both sides of that fence.

0:44Unidentified speaker (UNKNOWN): I'm

0:44Unidentified speaker (speaker_0): Basil Louis, investing globally from Singapore with an Asia angle. This is the East West Bio Brief, Biotech. and Beyond, for Friday, November 20th.

0:54Unidentified speaker (UNKNOWN): And

0:54Ning: I'm Ning, Basil's AI co host. Both our voices are AI clones, but Basil is the real person behind this show. Personal views, not investment advice.

1:09Unidentified speaker (speaker_0): Is a bipartisan advisory body set up by Congress with members of Congress and outside experts. This week it published an analysis with a press release titled China is Closing the Biopharma Innovation Gap.

1:22Ning: It looked at 57 licensing deals between 15 of the biggest drug makers in the US market and 42 Chinese biotech companies from January 2023 to October this year. Three findings. Deals are happening earlier, often before human trials. Upfront payments are rising, and deals are moving from one drug at a time to several drugs, whole platforms, and shared commercial rights.

1:53Unidentified speaker (UNKNOWN): So

1:53Unidentified speaker (speaker_0): why does that worry Washington? The Commission's argument is about know-how. Repeat partnerships, it says, can teach partners how to develop, register, and sell. medicines in the US. It compares this with US joint ventures in cars, chips, and industrial chemicals.

2:09Unidentified speaker (UNKNOWN): The

2:10Unidentified speaker (speaker_0): Commission's executive director, Caitlin Fraser, was blunt. US-China pharma deals, she said, are starting to favor the Chinese startups, and that risks eroding biotech RD in the US.

2:22Ning: The Commission also points to China's own plan. In September, China published a five year plan for its pharmaceutical industry with goals for more first in class drugs and more global sales by 2030.

2:41Unidentified speaker (speaker_0): So what does it actually want, Ning?

2:44Ning: Two things. First, it supports a rule the US Treasury proposed in October under a law. known as the Coins Act, to bring biotech into America's outbound investment program. It calls that a prudent step. Under that proposal, according to an analysis by the law firm Sidley, cited by Axios, cash licenses with milestones and royalties would still be allowed, equity stakes in Chinese firms would be barred, and some joint ventures could be covered too. Second, and this part gets less attention, it says the US must act now to outinnovate its competitors. So it's not only a fence, it's also a call to run faster.

3:29Unidentified speaker (speaker_0): Two cautions. This is an advisory body's analysis, and the Treasury rule is still a proposal. Public comments closed on December 7th. And it's Washington's view of these deals. The Commission itself acknowledges that partnering in China helps drug makers cut development costs and share risk, and Axios notes that Western companies see these deals as a way to share the work of drug discovery and check early results.

3:58Unidentified speaker (UNKNOWN): Now

3:58Ning: the other side, RA Capital, the Boston-based healthcare investor, has opened. an office in Shanghai. The South China Morning Post reports it opened in mid-October, and the firm now has 12 people in China, four of them investment professionals.

4:13Unidentified speaker (speaker_0): And the post describes RA Capital as one of the most vocal critics of Washington's growing scrutiny of US-China biotech collaboration. So while one part of America draws up the fence, an American investor is moving. closer to the science. Here's a way to see the commission's point in real numbers. Same buyer, two deals.

4:35Unidentified speaker (UNKNOWN): On

4:35Ning: Thursday, APV signed with Disco Pharmaceuticals in Cologne, Germany. Disco designs what it calls N-gated therapies. They are built to act only when a cell shows two tumor markers at once to spare healthy tissue. Disco gets 40. million up front and up to $2.5 billion in option and milestone payments plus royalties. Epvi can license programs after Disco finishes the research. Back in January, Epvi paid Rema Jen in Chinese, Rong Changshengwu, $650 million doll upfront for rights outside Greater China to RC-148, RC 148, a PD-1 and VE. VEGF bi-specific antibody, already in early clinical studies.

5:19Unidentified speaker (speaker_0): 650 million versus 40. It's not like for like. One drug is already in patients, the other is research with an option.

5:28Unidentified speaker (UNKNOWN): But

5:29Unidentified speaker (speaker_0): remember Thursday, Pfizer paid Stana $330 million upfront for programs not yet cleared for US trials. That's the trend the Commission is pointing at. Chinese science commanding bigger checks earlier.

5:41Ning: And from Europe, the same picture could look like an opening. What happens to companies like Disco if China deals get harder? That's a question for Monday's Weekly. Quick hits: Novartis Novatis held its investor day in London on Thursday. It now expects sales to grow 5%. a year at constant currencies from 2026 to 2031. It also raised its peak sales forecasts for three drugs: Casimta to $8 billion, and Scamblix and Legville to $5 billion each.

6:20Unidentified speaker (speaker_0): Reuters pointed out that 5% is the low end of the 5-6% range Novatis gave last year. for a slightly earlier period and the shares fell about 3%.

6:30Unidentified speaker (UNKNOWN): The

6:30Ning: East West detail. One of the pipeline drugs Novatis highlighted is QCZ484, a twice-yearly RNA silencer for high blood pressure. According to Argo Biopharma in Chinese Bo Wang Jiyou, Jiao. it came from Argo in Shanghai under a licensing deal with Novatis. Novartis, and its phase 2 trial lists four sites here in Singapore.

6:56Unidentified speaker (speaker_0): Next, Merck, known as MSD outside the US and Canada, has signed a research deal with Isomorphic Labs two days after Isomorphic's $5 billion raise. Isomorphic will design small molecules against one cancer target using some of Merck's own data, and Merck takes them through development. The upfront wasn't disclosed. Isomorphic says its work is setting the stage for clinical entry. So the step from computer to patient is still ahead.

7:24Ning: Sanofi. Bloomberg reports that Sanofi is weighing a takeover of InSMED, the US maker of Brin Supre, a pill for a chronic lung disease called bronchyactasis. bronchieactasis. Bloomberg sources say a deal could still be weeks away or may not happen at all. And both companies declined to comment to Fierce Pharma. InSMET's shares rose as much as 24%. And Mega Robo, in Chinese Meiji, raised nearly $200 million. Based in Suzhou, Sujo, it describes itself as building intelligence infrastructure. for the physical world, starting with AI-driven science labs. New investors include the Oman Investment Authority, Oman's Sovereign Wealth Fund, and CMB International. Mega Robo says it has raised about $600 million in total and is expanding. abroad. Robot labs are a threat we'll come back to soon.

8:33Unidentified speaker (speaker_0): One for our Brain Computer Interface Weekly on November 30th.

8:37Unidentified speaker (UNKNOWN): A

8:37Unidentified speaker (speaker_0): Hangzhou startup spun out of Zhejiang University has raised a series A of several hundred million yuan led by Shenzhen Capital Group for an implanted brain stimulator for treatment-resistant depression. Conventional deep brain stimulation. runs at fixed settings. This system, the company says, aims to read mood signals and stimulate only when needed. Its two devices are still in registration trials, not yet approved. So, back to the title: Good fences make good neighbors. The commission wants a fence and a faster runner. RA Capital wants a door. And Novartis's Investor Data. Day shows the science already crosses the fence. Watch for the December comment deadline for whether deal terms start to shift and for Sanofi's next move. I have no personal holding in any of the companies mentioned today. If this brief is useful, follow the East West Bio brief on Spotify or Apple Podcasts.

9:34Ning: And for the transcripts and sources, subscribe to our newsletter on LinkedIn. also called the East West Bio Brief. It goes out every Monday with our weekly roundup. That's today's brief. The key sources are in the show notes. See you tomorrow.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights